Development Project 3
Development Project 3
批准号:
8744898
负责人:
BETI THOMPSON
金额:
$20.46万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-25 至 2018-08-31
关键词:
AddressAfrican AmericanAndrogen ReceptorBiologicalBiological AssayBiologyBreastCXCR4 ReceptorsCXCR4 geneCadherinsCancer EtiologyCancer PatientCase-Control StudiesCell SurvivalChemotactic FactorsComplementary DNACyclinsDataDevelopmentDiseaseDisease ProgressionDuctalERBB2 geneEstradiol ReceptorsEstrogen Nuclear ReceptorEstrogen ReceptorsEstrogensEtiologyGene ExpressionGenomeGrowthGrowth FactorHistologicHormonesHumanImmunohistochemistryIn VitroLaboratoriesLatinaLeadLigandsLigationLobularMalignant NeoplasmsMammary NeoplasmsMeasuresMediatingMembraneMenopauseMentorshipMitogen-Activated Protein Kinase 3MolecularNeoplasm MetastasisNuclearPTEN genePathway interactionsPatientsPeptidesPhasePopulationPositive Lymph NodePreventionProgesteroneProgesterone ReceptorsProgestinsProtein IsoformsResearchRiskSRC geneScientistSignal TransductionSpecimenSteroid ReceptorsStromal Cell-Derived Factor 1TechniquesTestingTimeTrainingUnited StatesWomanWomen&aposs HealthWorkanticancer researchcancer cellcancer riskcarcinogenesiscareer developmentcell motilitygenome-widehormone therapymalignant breast neoplasmmembernovelpopulation basedprotein expressionrandomized trialreceptorreceptor expressionreproductiveresponsesteroid hormonetherapeutic targettumortumor progression
中文摘要
该项目的总体目的是促进我们对新型膜相关类固醇受体对乳腺癌进展多个阶段的影响的理解。黄体酮是膜相关类固醇受体的关键调节因子,妇女健康倡议(WHI)随机试验的数据强调了黄体酮在乳腺癌病因学方面的重要性,该试验表明,虽然使用雌激素和黄体酮联合绝经期激素治疗(CHT)会增加乳腺癌的风险,但单独使用雌激素不会。李博士和他的同事们领导了许多后续研究中的第一个,这些研究证明,外源性黄体酮使用与乳腺癌的风险相关,主要局限于小叶组织学类型乳腺癌的风险大幅增加。然而,黄体酮使用与小叶性乳腺癌风险之间的密切关系背后的生物学机制基本上是未知的。
英文摘要
The overarching purpose of this project is to advance our understanding of the influence of novel membrane associated steroid receptors on multiple phases of breast cancer progression. Progesterone is a key regulator of the membrane-associated steroid receptors and the importance of progesterone with respect to breast cancer etiology is highlighted by data from the Women's Health Initiative (WHI) randomized trials indicating that while use of combined estrogen and progestin menopausal hormone therapy (CHT) increases risk of breast cancer, use of estrogen alone does not. Dr. Li and his colleagues led the first of many subsequent studies to document that the risk of breast cancer associated with exogenous progestin use is primarily restricted to a more substantial increase in the risk of breast cancers of a lobular histologic type. However, the biological mechanisms underlying the strong relationship between progestin use and lobular breast cancer risk are essentially unknown.
The findings from our population-based breast cancer studies (Drs. Porter and Li) and from in vitro studies in Dr. Ashley's laboratory identifying the presence and importance ofthe MPRs and CXCL12 and its receptor, CXCR4 in hormone-regulated reproductive pathways, lead us to hypothesize that both membrane associated receptors and metastatic chemoattractants, such as hormone-regulated CXCL12 and CXCR4, contribute to the differential impact of CHT use on risks and biology of lobular vs. ductal breast cancer.
We plan to evaluate the contribution of membrane progesterone and estrogen receptor expression and downstream effects in relation to E+P use and histological subtype in well characterized ILC and IDC tumors from a large ongoing population-based study. Whole genome gene expression will be assessed in a subset of the ILC and IDC tumors to identify and characterize new factors and pathways relevant to the relationship between progesterone and breast cancer. This study will provide vital information relevant to breast cancer etiology and could lead to the identification of novel prevention and therapeutic targets. This project will also increase the capacity of NMSU to conduct competitive research through providing training on state of the art molecular techniques such as the DASL assay. Additionally, it partners a junior scientist. Dr. Ryan Ashley at NMSU, with two senior FHCRC scientists (Drs. Porter and Li) who will contribute directly to Dr. Ashley's career development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core B
-
批准号:8744874
-
项目类别:
-
资助金额:$17.91万
-
财政年份:2013
-
负责人:BETI THOMPSON
-
依托单位:
Development Project 4
-
批准号:8744899
-
项目类别:
-
资助金额:$17.11万
-
财政年份:2013
-
负责人:BETI THOMPSON
-
依托单位:
partnership for the advancement of cancer research
-
批准号:8744900
-
项目类别:
-
资助金额:$15.43万
-
财政年份:2013
-
负责人:BETI THOMPSON
-
依托单位:
Development Project 2
-
批准号:8744896
-
项目类别:
-
资助金额:$10.81万
-
财政年份:2013
-
负责人:BETI THOMPSON
-
依托单位:
Planning and Evaluation
-
批准号:8744893
-
项目类别:
-
资助金额:$9.08万
-
财政年份:2013
-
负责人:BETI THOMPSON
-
依托单位:
Development Project 1
-
批准号:8744894
-
项目类别:
-
资助金额:$8.22万
-
财政年份:2013
-
负责人:BETI THOMPSON
-
依托单位:
Outreach Core
-
批准号:8744902
-
项目类别:
-
资助金额:$7.82万
-
财政年份:2013
-
负责人:BETI THOMPSON
-
依托单位:
Training Program
-
批准号:8537571
-
项目类别:
-
资助金额:$1.86万
-
财政年份:2012
-
负责人:BETI THOMPSON
-
依托单位:
Administrative Core
-
批准号:8535128
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2012
-
负责人:BETI THOMPSON
-
依托单位:
Planning and Evaluation Core
-
批准号:8538016
-
项目类别:
-
资助金额:$17.0万
-
财政年份:2011
-
负责人:BETI THOMPSON
-
依托单位:
Planning and Evaluation Core
-
批准号:8538036
-
项目类别:
-
资助金额:$19.42万
-
财政年份:2011
-
负责人:BETI THOMPSON
-
依托单位:
Center for Hispanic Health Promotion: Reducing Cancer Disparities
-
批准号:8535123
-
项目类别:
-
资助金额:$73.41万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Center for Hispanic Health Promotion: Reducing Cancer Disparities
-
批准号:8917332
-
项目类别:
-
资助金额:$17.0万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Understanding and preventing breast cancer disparties in Latinas
-
批准号:8725067
-
项目类别:
-
资助金额:$169.66万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Center for Hispanic Health Promotion: Reducing Cancer Disparities
-
批准号:8136637
-
项目类别:
-
资助金额:$78.37万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Understanding and preventing breast cancer disparties in Latinas
-
批准号:8495071
-
项目类别:
-
资助金额:$184.66万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Understanding and preventing breast cancer disparties in Latinas
-
批准号:8296079
-
项目类别:
-
资助金额:$186.24万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Community Outreach Program
-
批准号:8034122
-
项目类别:
-
资助金额:$12.64万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Center for Hispanic Health Promotion: Reducing Cancer Disparities
-
批准号:8537569
-
项目类别:
-
资助金额:$1.86万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
Center for Hispanic Health Promotion: Reducing Cancer Disparities
-
批准号:9114192
-
项目类别:
-
资助金额:$27.45万
-
财政年份:2010
-
负责人:BETI THOMPSON
-
依托单位:
海外基金